Today: 20 May 2026
CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead
14 January 2026
2 mins read

CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

New York, January 14, 2026, 12:59 EST — Regular session

  • CompoSecure shares climbed roughly 8% following news the company secured a new debt package and confirmed plans for a corporate rebrand
  • New senior secured notes maturing in 2033 come with a 5.625% coupon; shares set to trade under the ticker “GPGI” starting Jan. 23
  • The recent Husky deal introduces a second reporting segment and unveils new governance terms in an SEC filing

Shares of CompoSecure, Inc climbed roughly 8% on Wednesday following the announcement of a refinancing that extends its debt maturities. The move came just days after the company finalized its acquisition of Husky Technologies.

This move is crucial as CompoSecure works to stabilize its balance sheet while transforming into a two-segment holding company. Investors are debating if the cheaper, longer-dated debt actually provides management with the flexibility to execute their plans or just extends the timeline.

The company said its subsidiary closed a $900 million private placement of senior secured notes due 2033, along with a new $1.2 billion term loan maturing the same year, and $400 million in revolving credit commitments due 2031. (Senior secured notes are bonds backed by collateral; a revolving loan is a credit line a company can draw and repay.)

The company said the notes were issued at par with a fixed 5.625% coupon. The new term loan carries a floating rate tied to term SOFR — a benchmark overnight interest rate — plus 2.25%, it added.

CompoSecure said it used proceeds and cash on hand to pay down its existing revolver and refinance its Term Loan B, covering fees and expenses as well. The company described the refinancing as a move to reduce its cost of capital and increase liquidity.

Just two days ago, CompoSecure announced it had closed its business combination with Husky, valuing the merged entity at $7.4 billion. The stock is set to start trading under the new name and ticker “GPGI” on Jan. 23. Executive Chairman Dave Cote and Chief Investment Officer Tom Knott emphasized the company’s ongoing commitment to “delivering results for our shareholders.” GlobeNewswire

A regulatory filing detailed the Husky deal, revealing the transaction included roughly $688.7 million in cash alongside 54,978,334 CompoSecure Class A shares. It also spelled out investor rights and resale terms that could influence future trading dynamics.

The filing also noted that the investor group earns board nomination rights when it hits specific ownership levels. It outlined registration rights that may pave the way for secondary offerings after the company files a resale shelf. Additionally, the private equity holder faces a 90-day lock-up period post-closing, with the possibility of early release.

CompoSecure climbed $1.74 to $23.17 around midday, even hitting $23.34 earlier. Meanwhile, the broader market struggled: the S&P 500 ETF SPY slipped roughly 1%, and tech-focused QQQ dropped about 1.6%.

One risk: some of the new debt carries a floating rate. So, if short-term interest rates move up, the cost of servicing the term loan could increase, even though the overall maturity schedule appears more manageable.

Traders will be keeping an eye on the timing of the company’s resale registration filing and the volume of shares that might hit the market once the lock-up period expires, provided it isn’t lifted ahead of schedule.

Next on the agenda: the rebrand’s mechanics, starting with the switch to the “GPGI” ticker at the open on Jan. 23. Additional updates on integration progress and leverage goals are expected to follow.

Stock Market Today

  • Tesla Q1 2026 Earnings Beat; Stock Faces Mixed Outlook for 2030
    May 20, 2026, 10:24 AM EDT. Tesla (TSLA) reported Q1 2026 earnings per share (EPS) of $0.41, exceeding the $0.36 consensus, with automotive gross margin rising to 21.1% from 16.2%. Operating income increased 135.8% year-on-year (YoY), and services plus Full Self-Driving (FSD) revenue jumped 42% to $3.75 billion, with 1.28 million active FSD subscriptions up 51%. Despite strong fundamentals, Tesla shares fell 8.83% year-to-date to $409.99 amid skepticism about AI monetization and scaling autonomy. Wall Street's average target is about $412, while a proprietary model estimates a base case price of $510 by 2030, with a bull case of $645. Achieving $650 requires significant price-to-earnings multiple expansion or sharp EPS growth from AI ventures, amid challenges like increased operating expenses and production constraints.

Latest articles

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

20 May 2026
POET Technologies shares rose 11% to $14.55 in early Nasdaq trading Wednesday after closing a US$400 million direct offering of 19 million shares and warrants. The rebound followed an 8% drop Tuesday on dilution concerns. The company reported Q1 revenue of $503,389 and a net loss of $12.3 million. A recent $50 million order from Lumilens could scale to $500 million over five years if production ramps up.
Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

20 May 2026
Nokia shares rose 3.37% in Helsinki trading Wednesday after the FCC conditionally approved its Beacons and ONT devices, exempting them from U.S. Covered List restrictions. Nokia also transferred 975,289 treasury shares to equity plan participants. Dell’Oro Group forecasts the optical transport equipment market will grow 16% in 2026, driven by AI data centers.
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

20 May 2026
Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next
Previous Story

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom
Next Story

Uber stock slips after NYC tipping report targets Uber Eats, as earnings date and new profit metrics loom

Go toTop